World Vaccine Europe 2021
Viroclinics-DDL will shed light on the topic: “Accessible & Agile SARS-CoV-2 Clinical Trial Supply Chains” on Day 3 of the conference [Oct 21st, at 10:00]. We will discuss the following topics:
- Pre-requisites of successful agility in clinical trials – ACCESSIBILITY in it’s broadest sense
- The importance of end-to-end supply chain solutions
- Post Pandemic agility – necessity of scalable outsourcing strategies
- And more …..
Meet our clinical trial, logistics experts and scientists at Booth 35.
Marc van Pruijssen, Director Global Logistics, Viroclinics Xellerate
Marc van Pruijssen holds a Bsc. In international marketing, as well as management & organizational sciences. He performed an Msc, studying Transport & Logistics at TIAS-NIMBAS in Tilburg. Before joining Viroclinics-DDL in 2020, he has been responsible for a variety of developing supply chain functions and new business set up: supply chain planning, transport and distribution center operations, strategy development, program management and new product introductions. Next to that he is Board member and VP Marketing of the Council of Supply Chain Management Professionals (CSCMP) Benelux Round Table.
Contact SpeakerThis form is currently undergoing maintenance. Please try again later.
OUR LATEST NEWS
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO), from Summit Partners.
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Today, Viroclinics-DDL, a global Contract Research Organization supporting clinical and preclinical studies for drug and vaccine development and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allows Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralised COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant will be used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant.